Overview

Less Sticking.3,‡ Less Buildup.2,††
More Efficient Procedures.2,‡

Nonstick nano-coating technology enhances the performance of the LigaSure™ Maryland jaw device.

The multifunctional LigaSure™ Maryland jaw device now delivers even greater procedural efficiency.1,2,§

Because — compared to the legacy device — the new nonstick nano-coated jaws:

  • Reduce eschar buildup2,††
  • Decrease instances of sticking3,‡
  • Lead to fewer jaw cleanings — and make cleanings easier3,§

So you get these benefits in addition to the performance you expect from the LigaSure™ Maryland jaw device.

Features

Enhanced Dissection.([FOOTNOTE=Based on internal test report #R0035742, Maryland validation labs: Independent surgeon feedback collected during porcine labs in Houston and Los Angeles. April 16 to 18 and April 30 to May 3, 2013.],[ANCHOR=],[LINK=]),Ω 
Intuitive Control.4,††
Greater Efficiency.2,§

Every feature of the nonstick nano-coated LigaSure™ Maryland jaw device is designed to benefit you and patients.

We engineered our multifunctional LigaSure™ Maryland jaw device to provide efficiency throughout the procedure.([FOOTNOTE=Based on internal test report #RE00071598, Maryland validation labs: Independent surgeon feedback collected during porcine labs in Houston and Los Angeles. April 16 to 18 and April 30 to May 3, 2013.],[ANCHOR=],[LINK=]),§§ Now, we’ve taken that efficiency to the next level — by putting nonstick nano-coating on the jaws.2,§

Multifunctional flexibility

With the LigaSure™ Maryland jaw device you get the benefits of:

  • A one-step vessel sealer1
  • A Maryland dissector for enhanced blunt dissection4,Ω
  • An atraumatic grasper to securely grasp tissue4,ΩΩ
  • Cold scissors to leave the critical decision to cut in your hands1,5,†††

Multifunctional performance

The LigaSure™ Maryland jaw device delivers5:

  • Improved access compared to straight jaws††
  • Improved tip visualization compared to straight jaws‡‡‡
  • A jaw designed to follow the curvature of the uterus or stomach‡‡‡
  • Easy skeletonization of vessels‡‡‡
  • A nonstick nano-coating for improved efficiency§§

Three lengths to meet different procedural needs

The LigaSure™ Maryland jaw device is available in three lengths:

  • 23 cm
  • 37 cm
  • 44 cm
/content/dam/covidien/library/global/en/product/vessel-sealing/ligasure-maryland-jaw-front-tip-f.jpg

Order Information

Technology

Reliable Performance. Greater Efficiency.2,§

We added nonstick nano-coating technology on the LigaSure™ Maryland jaw device to help you tackle challenges both big and small.

The new LigaSure™ Maryland jaw device is designed to help you treat patients — reliably and efficiently.2,§

Because we combined the benefits of nonstick nano-coating technology with the proven performance of LigaSure™ vessel-sealing technology.

Nano-coating is a highly controlled, thin-film coating with uniform thickness. It covers the entire jaws of a LigaSure™ device without impacting the intelligent vessel-sealing algorithms of Valleylab™ energy platforms.([FOOTNOTE=Based on internal test report #RE00070396 Rev A, Verification of the LF1923/LF1937/LF1944 Maryland devices in a renal bench burst study: iterations Maryland. Nov. 7–10, 2016.],[ANCHOR=],[LINK=])

Reduce sticking3,‡ improve efficiency2,§

For the LigaSure™ Maryland jaw device, compared to its uncoated counterpart, that means: 

  • Less eschar buildup2,††
  • Less sticking3,‡
  • Fewer jaw cleanings3,§

The net benefit is smoother, more efficient procedures.2,§

The confidence of control and consistency

LigaSure™ technology has been setting the standard of care for vessel sealing for nearly two decades.

LigaSure™ technology uses the body’s own collagen and elastin to create a permanent seal that can withstand three times normal systolic blood pressure.([FOOTNOTE=Based on internal test report #R0064457, LigaSure™ device renal bench burst pressure evaluation of the Valleylab™ FT10 energy platform. May 3, 2015.],[ANCHOR=],[LINK=]) It’s been used in more than 19 million procedures worldwide.([FOOTNOTE=Based on internal report #US161132(1), Sales data from FY01 to FY17. July 2017.],[ANCHOR=],[LINK=]),§§§ And is supported by an ever-growing body of clinical evidence.

With an average seal cycle of one to four seconds in most surgical situations,([FOOTNOTE=Based on internal test report #RE00025819 Rev A, LigaSure™ device data sources for VLFT10 white papers. September 2015.],[ANCHOR=],[LINK=]) LigaSure™ technology can seal vessels up to and including 7 mm, lymphatics, and tissue bundles. It also eliminates the guesswork — and minimizes thermal spread([FOOTNOTE=Based on internal test report #RE00005503, Verification report: GLP acute animal lab: LigaSure™ device preclinical evaluation of Valleylab™ FT10 energy platform. May 19, 2015.],[ANCHOR=],[LINK=]) — by automatically discontinuing energy delivery when the seal cycle is complete.9

Made even better by the Valleylab™ FT10 energy platform

The LigaSure™ Maryland jaw portfolio works great when powered by the ForceTriad™ energy platform with 3.6 software and higher. For optimal performance, use it with the Valleylab™ FT10 energy platform.

The Valleylab™ FT10 energy platform makes LigaSure™ devices better than ever.9,([FOOTNOTE=Based on internal test report #RE00005401 Rev A, Product validation of Valleylab™ FT10 energy platform: surgeon and nurse evaluation in simulated use. Jan. 27 to 30, 2015 and Feb. 24 to 27, 2015.],[ANCHOR=],[LINK=])

LigaSure™ Maryland Jaw Device Seal Strength Comparison

Find out how the LigaSure™ Maryland Jaw device stacks up against the competition.

  • † Eschar buildup assessed using optical imaging analysis after 60 seal and divide cycles.

  • ‡ Instances of tissue sticking to jaws measured over 110 seals per device.

  • § Cleaning effectiveness assessed after each of two cleaning cycles.

  • Ω When compared to the surgeon’s primary device, 23 out of 32 surveyed agreed.

  • †† 31 out of 33 surgeons surveyed agreed.

  • §§ 32 out of 32 surgeons surveyed agreed.

  • ΩΩ 33 out of 33 surgeons surveyed agreed. 

  • †† 21 out of 32 surgeons surveyed agreed.

  • ‡‡‡ 30 out of 33 surgeons surveyed agreed.

  • ‡‡‡ Based on data from 2001 through FY17.